Displaying 118 (all) recruiting clinical trials.
-
A Phase 3 Single-Arm Multiple-Dose Pharmacokinetic Comparability Trial Between TAK-881 and HYQVIA in Adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy
The MIgGRATE Study is a clinical study for adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) of an investigational drug called TAK-881. In this study, TAK-881 ... -
A Randomized Open-label Multicenter Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-na ve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)
This is a Phase 2 study testing two different medicines to treat a blood cancer called GCB DLBCL(diffuse large B-cell lymhoma). Zilovertamab Vedotin (an ...
-
A Randomised Open-Label Phase III Study of Saruparib (AZD5305) Plus Camizestrant compared with Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1 BRCA2 or PALB2 Mutations and Hormone Receptor Positive HER2-Negative (IHC 0 1+ 2+/ ISH non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)
This study is testing how well a new medicine, saruparib (AZD5305), works when combined with camizestrant compared to other common treatments for advanced breast cancer ...
-
Global Phase 3 Randomized Open-Label Study to Evaluate Efficacy & Safety of Firmonertinib Comp.w/ Osimertinib or Afatinib as 1st line Treat. in Pts. w/ Locally Advanced or Metastatic NSCLC with EGFR PACC Uncommon Mutations (Alpacca)
This is a Phase 3 study testing the safety and effectiveness of the new medicine firmonertinib (an EGFR-tyrosine kinase inhibitor) and comparing it with standard ...
-
A double blind randomised placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD)
The purpose of this research study is to test a new drug called nerandomilast in participants with Systemic Auto-immune Rheumatic Diseases associated Interstitial Lung Diseases ... -
Interventional randomized double-blind placebo-controlled optional open-label extension trial of Lu AF82422 in participants with Multiple System Atrophy.
The purpose of this trial is to investigate whether Lu AF82422 is safe and effective in treating patients with multiple system atrophy (MSA). This trial ... -
A Phase III Randomised Double-blind Placebo-controlled Event-driven Study to Assess the Efficacy Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants with Chronic Kidney Disease and High Blood Pressure
The purpose of this study is to investigate the efficacy, safety and tolerability of baxdrostat in combination with dapagliflozin, compared with placebo and dapagliflozin intreating ... -
A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Investigate the Efficacy Safety and Tolerability of LP352 in the Treatment of Seizures in Children and Adults with Dravet Syndrome
The purpose of this study is to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children (2-17) and adults ... -
EMPEROR: A Multicenter Randomized Double-blind Sham-controlled Parallel Group Phase 3 Study Evaluating the Efficacy Safety and Tolerability of Zorevunersen (STK-001) in Patients with Dravet Syndrome
The purpose of the EMPEROR Study is to assess the investigational medicine, Zorevunersen, to see:- whether it can reduce or prevent motor seizures when given ...
-
An Open-Label Randomized Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy VS Surgery and Adjuvant Therapy in Clinical Stage IIIB/C/D Melanoma Patients
The primary objective of the study is to demonstrate that a neoadjuvant Daromun treatment followed by surgery and adjuvant therapy improves in a statistically significant ...